We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors (SGT94-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01517464
Recruitment Status : Completed
First Posted : January 25, 2012
Last Update Posted : April 26, 2017
Information provided by (Responsible Party):
SynerGene Therapeutics, Inc.

Brief Summary:
This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer. In addition, we will look for evidence of RB94 expression within tumor tissue after systemic administration of SGT-94.

Condition or disease Intervention/treatment Phase
Neoplasm Genetic: SGT-94 Phase 1

Detailed Description:

RB94, a tumor suppressor gene, is a modified form of the retinoblastoma gene, RB110. RB94 has shown enhanced tumor suppressor and tumor cell killing activity compared to RB110 in all tumor cell types studied to date, including bladder cancer cell lines. Moreover, RB94 has shown no toxicity to any normal human cells tested.

SGT-94,the agent being tested, is a systemically administered complex composed of the RB94 gene (plasmid DNA)encapsulated in a liposome that is targeted to tumor cells by means of an anti-transferrin receptor single chain antibody fragment (TfRscFv)attached to the outside of the liposome. Pre-clinical in vivo efficacy studies have indicated that SGT-94, when systemically administered, preferentially targets tumor cells and efficiently transfects them. This results in cancer cell death via mechanisms that are unique for RB94 and also increases the tumor's response to conventional radiation and chemotherapy.

This Phase I study is designed to evaluate the safety of SGT-94 and to establish a practically attainable and/or tolerable dose of this anti-cancer agent for use in further clinical trials. Additionally, evidence of RB94 expression within tumor tissue after systemic administration of SGT-94 will be sought, and clinically observable anti-cancer effects in patients will be documented. Enrollment will be targeted to individuals with "RB negative" tumors, i.e. tumors in which there is no staining for RB protein by immunohistochemistry (IHC). Preference will be given to patients with tumors in a location amenable to biopsy following treatment with SGT-94. This would include the prostate, bladder, superficial lymph nodes and any mass suitable for fine needle aspiration under CT or ultrasound guidance, or any lesion reachable by endoscopy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
Study Start Date : January 2012
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SGT-94
Dose escalation of experimental therapeutic SGT-94 to assess safety
Genetic: SGT-94
SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.

Primary Outcome Measures :
  1. Severity of Adverse Events [ Time Frame: 4 weeks each patient ]
    The severity of adverse experiences in each patient will be determined based upon changes in the results of clinical laboratory tests and physical examnations. These findings will be used to determine the safety and tolerability of increasing doses of SGT-94.

Secondary Outcome Measures :
  1. Clinical Response [ Time Frame: Week 4 ]
    Clinical Response will be assessed according to standard criteria for the particular solid tumor. In general, Response Evaluation Criteria in Solid Tumors (RECIST) criteria will be used.

  2. Changes in Tumor Markers [ Time Frame: Week 4 ]
    When appropriate, changes in tumor markers between the values measured at baseline and at week 4 following the cycle of SGT-94 infusion will be assessed.

  3. Expression of RB94 in Tumor Biopsies [ Time Frame: Week 2 ]
    Tumor targeting and uptake of SGT-94 by the tumor cells will be determined using Immunohistochemistry to assess the expression of RB94 in any tumor biopsies obtained during the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic proof of cancer for which no standard therapy is available, and which shows no staining for RB by IHC.
  • Spirometry with at least 70% of predicted volumes (including FEV1). A left ventricular ejection fraction (LVEF) of 45% or more. All patients will have a screening 2-D Echocardiogram as part of eligibility screening.
  • Patients must have adequate physiologic reserve as evidenced by:

    • Zubrod Performance Status (PS) of </= 2; or 3 if of recent onset (i.e. < 2 weeks) and if the compromised performance status is related to uncontrolled pain which is expected to come under control by means of improved pain management.
    • Laboratory values meeting the following criteria:

      • Absolute neutrophil count >/= 1,200/mm3
      • Platelet count >100,000/mm3.
      • AST and ALT </= 3x the upper limit of normal
      • Conjugated bilirubin </= 1.5 mg/dL (or total bilirubin </= 2.5 mg/dL)
      • Native kidney function producing creatinine clearance (either measured or estimated by Cockcroft formula) of at least 40 mL/min. Cockcroft formula: CLcr = [(140-age) • wt(kg)]/[72 •Creat (mg/dL)] (For females, multiply by 0.85)
      • Hemoglobin >/= 10.0 g/dL without transfusion support
      • White blood cell count > 3.0 k/mm3
      • PT and aPTT each < 1.5 times the upper limit of normal.
  • Women of child-bearing potential must have a negative pregnancy test.
  • Male and female patients reproductive potential must agree to use measures to avoid pregnancy throughout the study and for 3 months following discontinuing study drug.
  • Patients must have recovered from any previous therapy side effects or toxicities prior to initiating protocol study infusions.
  • Life expectancy > 12 weeks.
  • Organ function </= grade 1.
  • Age of </= 18 years.

Exclusion Criteria:

  • Some prior cancer therapies are not consistent with eligibility; specifically:

    • At least 30 days must have elapsed since any prior experimental therapy
    • At least 6 weeks must have elapsed since prior systemic mitomycin C
    • At least 8 weeks must have elapsed since any dose of Strontium-89
    • At least 4 weeks must have elapsed since prior Sm-153 lexidronam (Quadramet™)
    • At least 4 weeks must have elapsed since prior radiotherapy
    • Any prior exposure to gene vector delivery products
  • Pregnancy or lactation
  • Serious concurrent medical illness that in the opinion of the investigator would compromise patient safety or preclude accurate assessment of outcome.
  • Patients with the following manifestations of cardiovascular disease are excluded:

    • Myocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than 45% secondary to a more remote MI.
    • Any history of CVA or TIA in previous six months
    • New York Heart Association grade 2 or greater congestive failure
    • Unstable angina defined as angina (or anginal equivalent) 2 or more times per week despite medical therapy.
    • Echocardiographic evidence of pulmonary hypertension.
    • Diastolic dysfunction felt to contribute to any clinical sign or symptom.
    • Uncontrolled hypertension, defined as systolic BP >140 or diastolic >90 despite therapy.
  • Serious concurrent psychiatric disorder that in the opinion of the investigator would compromise patient safety or preclude accurate assessment of outcome.
  • Supraphysiologic doses of glucocorticoids (defined as > 30 mg of hydrocortisone per day or > 7.5 mg of Prednisone per day, or equivalent doses of other agents) or exposure to other immunosuppressive medications in the previous 30 days.
  • Requirement for anticoagulant therapy other than low intensity treatment to maintain patency of central venous catheters.
  • Treatment with antibiotics for proven infection within 1 week prior to study entry or signs and symptoms consistent with an active infection or fever > 38.1 C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01517464

Layout table for location information
United States, Texas
University of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
SynerGene Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: Arlene Siefker-Radtke, M.D. M.D. Anderson Cancer Center
Layout table for additonal information
Responsible Party: SynerGene Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01517464    
Other Study ID Numbers: SGT94-01
First Posted: January 25, 2012    Key Record Dates
Last Update Posted: April 26, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by SynerGene Therapeutics, Inc.:
bladder cancer
advances solid tumors
Additional relevant MeSH terms:
Layout table for MeSH terms